

Cloning of a γ -aminobutyric acid type C receptor subunit in rat retina with a methionine residue critical for picrotoxinin channel block

(ρ subunits/inhibitory neurotransmission/ligand-gated chloride channels, GABA receptor)

DONGXIAN ZHANG, ZHUO-HUA PAN, XISHAN ZHANG, AMY D. BRIDEAU, AND STUART A. LIPTON*

Laboratory of Cellular and Molecular Neuroscience, Children's Hospital and Program in Neuroscience, Harvard Medical School, Boston, MA 02115

Communicated by George Wald, Harvard University, Cambridge, MA, August 11, 1995

ABSTRACT Ionotropic receptors for γ -aminobutyric acid (GABA) are important to inhibitory neurotransmission in the mammalian retina, mediating GABA_A and GABA_C responses. In many species, these responses are blocked by the convulsant picrotoxinin (PTX), although the mechanism of block is not fully understood. In contrast, GABA_C responses in the rat retina are extremely resistant to PTX. We hypothesized that this difference could be explained by molecular characterization of the receptors underlying the GABA_C response. Here we report the cloning of two rat GABA receptor subunits, designated $\rho 1$ and $\rho 2$ after their previously identified human homologues. When coexpressed in *Xenopus* oocytes, $\rho 1/\rho 2$ heteromeric receptors mimicked PTX-resistant GABA_C responses of the rat retina. PTX resistance is apparently conferred in native heteromeric receptors by $\rho 2$ subunits since homomeric $\rho 1$ receptors were sensitive to PTX; $\rho 2$ subunits alone were unable to form functional homomeric receptors. Site-directed mutagenesis confirmed that a single amino acid residue in the second membrane-spanning region (a methionine in $\rho 2$ in place of a threonine in $\rho 1$) is the predominant determinant of PTX resistance in the rat receptor. This study reveals not only the molecular mechanism underlying PTX blockade of GABA receptors but also the heteromeric nature of native receptors in the rat retina that underlie the PTX-resistant GABA_C response.

γ -Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system (1). In the GABA receptor family, the GABA_A receptor gates a Cl⁻ channel, while the GABA_B receptor is coupled to a guanine nucleotide binding protein (2). These receptors have been characterized by their differential responses to selective agonists and antagonists. GABA_A-mediated responses can be blocked by a selective antagonist, bicuculline, and GABA_B-mediated effects can be activated by a specific GABA analog, baclofen (3). Recently, a third type of GABA response has been described that, unlike the others, is bicuculline and baclofen insensitive and has been designated GABA_C (2, 4). Like GABA_A, the GABA_C response is mediated by a Cl⁻ current, but the pharmacology is clearly different. GABA_C responses were first reported in the retina (5–12) but recently have also been found in the hippocampus (13).

GABA ρ subunits, cloned from the human retina by Cutting and colleagues (14–17), have been postulated to underlie GABA_C responses. The pharmacology of human ρ receptors is similar to that reported for GABA_C responses of rat and fish retinal neurons or *Xenopus* oocytes injected with bovine retinal mRNA (5–7, 14, 16, 17). Strikingly, however, GABA_C responses are quite sensitive to picrotoxinin (PTX) in each of these preparations except rat retinal neurons (6, 8). Although

PTX is thought to block vertebrate GABA receptors by acting directly or allosterically in the channel (4, 18), the molecular mechanism of its action is still not completely understood. Human ρ subunits are capable of forming functional homomeric receptors, but heretofore the native subunit composition of receptors formed from ρ subunits was not clear. One hypothesis for the difference in PTX sensitivity of rat GABA_C responses involves formation of heteromeric receptors (6). Thus, we searched for possible variants of GABA ρ subunits in the rat retina.

Here we report the cloning of two GABA subunits from the rat retina that are homologous to the previously reported human ρ subunits (14, 15). Most importantly, one of the rat subunits, unlike its human homologue, contains a single amino acid difference of fundamental importance to the pharmacology of the native responses. Functional expression in *Xenopus* oocytes demonstrated that this subunit ($\rho 2$) is responsible for PTX resistance of the rat receptor. Site-directed mutagenesis confirmed that PTX resistance in the native receptor is determined by a single amino acid, a methionine instead of a threonine in the second membrane region (M2) of the $\rho 2$ subunit compared to the $\rho 1$ subunit. Preliminary reports of our findings have been presented (19, 20).[†]

MATERIALS AND METHODS

cDNA Cloning. Reverse transcription PCR experiments were conducted using postnatal day 12 rat retinal total RNA with forward (5'-TGCNACATGGACTTCNGCC-3') and reverse (5'-CGAACACAAAGCTGACCCAG-3') primers based on the sequence of the human GABA $\rho 1$ subunit (N = mixed nucleotides of G, C, A, and T). cDNA fragments thus obtained were subcloned, sequenced, and used as probes to screen a λ ZAP II (Stratagene) rat retinal cDNA library. Bluescript plasmids were excised from positive clones and analyzed by automated sequencing to yield the rat $\rho 1$ subunit. Point mutations were introduced into cDNA clones by double-stranded, site-directed mutagenesis (Stratagene) and confirmed by sequencing.

In Vitro Transcription, Expression, and Oocyte Recording. Rat ρ subunits were studied by using a two-microelectrode voltage clamp in the *Xenopus laevis* oocyte expression system 2–9 days after injection of 20–60 ng of complementary RNA (cRNA) (21). Drugs were applied via a rapid superfusion system. Data were sampled at 2.2–11.1 Hz at room temperature.

Abbreviations: GABA, γ -aminobutyric acid; PTX, picrotoxinin; $\rho 1$, human GABA $\rho 1$ subunit; $\rho 1$, rat GABA $\rho 1$ subunit; cRNA, complementary RNA.

*To whom reprint requests should be addressed at: Children's Hospital, 300 Longwood Avenue, Enders Building, Suite 361, Boston, MA 02115.

[†]The sequence reported in this paper has been deposited in the GenBank data base (accession no. U21070).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

RESULTS

Cloning Rat GABA ρ Subunits. Screening a rat retinal cDNA library with probes obtained by reverse transcription PCR, we isolated clones of high sequence identity with the previously cloned human GABA ρ subunits (14, 15). One of these clones contained an open reading frame of 1422 bp encoding a predicted protein of 474 amino acids. This protein shared 95% (449/473) identical amino acids with the human $\rho 1$ receptor subunit (h $\rho 1$) and was therefore designated rat $\rho 1$ (r $\rho 1$; Fig. 1). The major differences between h $\rho 1$ and r $\rho 1$ occurred near the N terminus and between M3 and M4; the conserved regions among all GABA receptors, such as the Cys-Cys loop and the membrane regions, were preserved. The nonidentical amino acid residues did not alter the predicted functional motifs, including glycosylation and phosphorylation sites (14). A second clone, designated r $\rho 2$, had a deduced amino acid sequence that shared 91% (423/465) amino acid identity and the same length as h $\rho 2$ (Fig. 1) (15). Comparison of h $\rho 2$ and

Rat $\rho 1$...MKFGIFLLWGWVLAESTVHWPGREVHEPSKKGSRPQRQRGAHD	46
Human $\rho 1$...MRFGI_LWGWVLAAT_RMHWPGREVHEMSKKG_R_Q_O_REVHE	45
Rat $\rho 2$	MPYFMRLLAL...FCLMALV_R.....K_R_K_WTGHL	32
Human $\rho 2$	MPYFTRLIL...FCLMLV_L_R.....K_K_K_WTGQV	32
Rat $\rho 1$	DAHKGQSPILKRSSDITKSPITKSEQLLRIDHDFSMRPGFGGPAIPGVG	96
Human $\rho 1$	DAH_QV_PILRRSP_I_SPLT_SEQ_IDD_S_G	95
Rat $\rho 2$	ETS_P_HLYKKNL_V_IRTG_PRP_VED_T_A	81
Human $\rho 2$	EMP_P_HLYKKNL_V_IRKG_POQ_VDE_S_A	81
Rat $\rho 1$	DVQVESLDSISEVDMDFMTMLYLRYHWKDERLSFPSTNNLSMTFDGRLVK	146
Human $\rho 1$	_____K_S_P_TN_L	145
Rat $\rho 2$	_____R_A_P_SS_R	131
Human $\rho 2$	_____K_A_S_AS_K	131
Rat $\rho 1$	KIWVPMDFVHVKRSFIHDITTDNVMLRVQPDGKVLVSLRVTVTAMCNMD	196
Human $\rho 1$	_____M_____I_____V_____Q_____K_____L_V	195
Rat $\rho 2$	_____V_____T_____I_____F_____H_____M_____I	181
Human $\rho 2$	_____V_____T_____I_____F_____H_____M_____I	181
Rat $\rho 1$	FSRFPLDTQCSLEIESYAYTEDDLMLYWKGNDSLKTDERISLSQFLIQ	246
Human $\rho 1$	_____R_____T_____I_____ED_____Y_____K_____ND_____R	245
Rat $\rho 2$	_____H_____S_____L_____DE_____Y_____N_____DE_____K	231
Human $\rho 2$	_____H_____S_____L_____DE_____H_____N_____DE_____K	231
Rat $\rho 1$	EFHTTTLKAFYSSTGWYNRLYINFTLRRHIFFLQTYFPATMLVMSWV	296
Human $\rho 1$	_____E_____TK	295
Rat $\rho 2$	_____K_____SR	281
Human $\rho 2$	_____K_____SR	281
Rat $\rho 1$	SFWIDRRVAVPARVPLGTTVLTMTSTIITGVNASMPRVSYIKAVDIYLWVS	346
Human $\rho 1$	_____R_____P_____T_____S_____IK	345
Rat $\rho 2$	_____H_____S_____M_____S_____IR	331
Human $\rho 2$	_____R_____S_____T_____T_____VK	331
Rat $\rho 1$	FVFVFLSVLEAAVNYLTTVQERKERKLEKISCTCGLPQPRGVMLDSSY	396
Human $\rho 1$	_____R_____Q_____E_____LP_____TS_____LPPPTAM_____GN	395
Rat $\rho 2$	_____Q_____R_____D_____FP_____TC_____MLHSRTMT_____GS	381
Human $\rho 2$	_____R_____R_____E_____FP_____MC_____MLHSKTMM_____GS	381
Rat $\rho 1$	SDGEVNDLGGY...MPENGEKPRMMVQLTLASERGSPPQRKSRQGSYVS	442
Human $\rho 1$	_DG_V_D_DN...MPENG_KP_RMM_Q_T_AS_RSSPQR_SQRSSYVS	441
Rat $\rho 2$	_ES_A_S_AG_PRSHTLPEE_RQ_KIV_H_A_NS_LTSRRK_GLLKGQMG	431
Human $\rho 2$	_ES_A_S_AG_PRSHTLTEE_RQ_KIV_H_G_SG_ANAARK_GLLKGQMG	431
Rat $\rho 1$	MRI...NTHAIDKYSRIIFPAAYILFNLIYSIFS	474
Human $\rho 1$	MR...D_____I_____A_____L_____I	473
Rat $\rho 2$	L_V_FQN_____L_____F_____V_____V	465
Human $\rho 2$	FR_FQN_____L_____S_____F_____V_____V	465

FIG. 1. Comparison of deduced amino acid sequences of the GABA $\rho 1$ and $\rho 2$ subunits from human and rat. Conserved amino acids are listed only for $\rho 1$. Differences between homologous subunits of different species are indicated (* for $\rho 1$ vs. h $\rho 1$ and # for $\rho 2$ vs. h $\rho 2$). The regions of the Cys-Cys loop (dashed line) and the four proposed membrane-spanning motifs (solid lines) are preserved across the human and rat genes.

$\rho 2$ revealed one additional phosphorylation site for cAMP-dependent kinase in $\rho 2$ between M3 and M4. Like the human ρ subunits, $\rho 1$ and $\rho 2$ were quite similar to each other, especially in the membrane-spanning regions. Thus, we were surprised to find a methionine in $\rho 2$ in place of a threonine in $\rho 1$ at a site that is highly conserved among all other ligand-gated Cl⁻ channels in the M2 region.

Pharmacology of Recombinant Rat GABA ρ Subunits. In oocytes, $\rho 1$ subunits, but not $\rho 2$ subunits, formed functional homomeric GABA receptors. Many characteristics of homomeric $\rho 1$ receptors were similar to those of human ρ receptors (16, 17), to GABA_C responses encoded by bovine retinal mRNA (7), and to GABA_C responses of primary retinal neurons (5, 6, 8-12). These properties included little if any desensitization to GABA and insensitivity to diazepam or pentobarbital (data not shown). The GABA dose-response curve for homomeric $\rho 1$ receptors was well fit by the Hill equation with EC₅₀ = 1.1 ± 0.1 μM (mean ± SEM; n = 17 oocytes) and a Hill coefficient of 2.3 ± 0.1 (Fig. 2A). Although this EC₅₀ was slightly lower than those of their human $\rho 1$ and $\rho 2$ counterparts, reported to be 1.8 and 1.7 μM, respectively (17), the Hill coefficient was nearly identical (17). However, unlike the native GABA_C responses of rat retinal neurons (6, 8), homomeric $\rho 1$ receptors were relatively sensitive to PTX, similar to receptors formed from h $\rho 1$ or h $\rho 2$ subunits. PTX




FIG. 2. GABA dose-response curve and PTX dose-inhibition curve for homomeric $\rho 1$ receptors. (A) GABA activates $\rho 1$ homomeric receptors with EC₅₀ = 1.1 ± 0.1 μM (mean ± SEM; n = 17 oocytes) and a Hill coefficient of 2.3 ± 0.10. GABA responses were normalized to that of 100 μM GABA for each oocyte. (B) Dose-dependent inhibitory effects of PTX on GABA-evoked currents from homomeric $\rho 1$ receptors. IC₅₀ values of PTX for 1, 2, and 20 μM GABA were 0.52 ± 0.10 (n = 4), 1.1 ± 0.1 (n = 6), and 40.0 ± 5.5 (n = 8), respectively.

inhibition of homomeric $\rho 1$ responses was dependent on GABA concentration (Fig. 2B), similar to homomeric $h\rho 1$, $h\rho 2$, and other preparations (7, 9, 16, 17).

$\rho 2$ Subunits Confer PTX Resistance. Although $\rho 2$ subunits did not form functional homomeric receptors, coexpression of $\rho 1/\rho 2$ resulted in heteromeric GABA receptors that were resistant to PTX. We initially evaluated PTX sensitivity by using 100 μM PTX to block 2 μM GABA-evoked currents; responses in oocytes injected with $\rho 1$ cRNA alone were almost completely blocked under these conditions (Fig. 3A). As we increased the percentage of $\rho 2$ coinjected with $\rho 1$ cRNA, the proportion of PTX-resistant GABA current increased (Fig. 3B and C). The dependence of PTX resistance on $\rho 2$ was evaluated quantitatively (Fig. 4A). The receptors underlying




FIG. 3. Correlation of PTX resistance with the percentage of $\rho 2$ or mutated $\rho 1(\text{T314M})$ cRNA coinjected with $\rho 1$ cRNA into *Xenopus* oocytes. A total of 30 ng of cRNA was injected into each oocyte, except in C and F where 60 ng was injected to increase the amplitude of the currents. PTX (100 μM ; solid bar) was used to test the antagonist sensitivity of the responses to GABA (2 μM ; open bar). (A) For homomeric $\rho 1$ receptors, PTX at a concentration of 100 μM almost totally blocked current evoked by 2 μM GABA (degree of inhibition, $99.3\% \pm 0.3\%$, mean \pm SEM; $n = 6$). (B) PTX blocked $74\% \pm 1.9\%$ ($n = 6$) of the GABA-evoked current when 50% $\rho 1$ cRNA was coinjected with 50% $\rho 2$ cRNA. (C) PTX blocked $51\% \pm 4\%$ ($n = 7$) of the GABA-evoked current when 25% $\rho 1$ cRNA was coinjected with 75% $\rho 2$ cRNA. (D) PTX blocked $78\% \pm 0.6\%$ ($n = 4$) of the GABA-evoked current when 10% wild-type $\rho 1$ cRNA was coinjected with 90% mutated $\rho 1(\text{T314M})$ cRNA. (E) PTX blocked $64\% \pm 2.3\%$ ($n = 4$) of the GABA-evoked current when 80% wild-type $\rho 1$ cRNA was coinjected with 20% $\rho 1(\text{T314M})$ cRNA. (F) PTX blocked $36\% \pm 4.0\%$ ($n = 7$) of the GABA-evoked current when 50% wild-type $\rho 1$ cRNA was coinjected with 50% $\rho 1(\text{T314M})$ cRNA. GABA-evoked currents became smaller in magnitude as the percentage of mutated cRNA increased.




FIG. 4. Composition of ρ subunits influences the proportion of GABA current not blocked by a fixed concentration of PTX and the dose-inhibition curve of PTX. (A) Plot of the GABA current remaining in the presence of 100 μM PTX vs. percentage $\rho 2$ cRNA (open triangles) or $\rho 1(\text{T314M})$ cRNA (solid circles) coinjected with $\rho 1$ cRNA. GABA responses were normalized to the maximal current evoked in each oocyte. (B) Dose-inhibition curves of PTX for 2 μM GABA responses from receptors expressed after coinjection of 25% $\rho 1$ cRNA and 75% $\rho 2$ cRNA (open triangles), coinjection of 25% $\rho 1$ and 75% $\rho 1(\text{T314M})$ (solid triangles), or injection of $\rho 1$ subunits alone (solid circles). The dose-inhibition curve of PTX for $\rho 1/\rho 2$ subunits displays two components. IC_{50} of PTX for $\rho 1/\rho 1(\text{T314M})$ subunits was 634 ± 34 μM ($n = 8$).

the component of GABA current blocked by PTX may be composed predominantly of homomeric $\rho 1$ subunits. This is suggested because the PTX dose-inhibition curve after coinjection of ρ subunits [$\rho 1(25\%)/\rho 2(75\%)$; Fig. 4B] contained two components, one similar to that of homomeric $\rho 1$ receptors (Fig. 4B) and a second shifted dramatically to the right.

Although the EC_{50} for heteromeric $\rho 1/\rho 2$ receptors was similar to that of homomeric $\rho 1$ receptors, the absolute magnitude of GABA-evoked currents decreased as the proportion of injected $\rho 2$ results increased. This finding suggests that the presence of $\rho 2$ results in a lower efficiency of receptor assembly, as recently proposed (17, 22). Alternatively, the presence of $\rho 2$ may alter receptor-ionophore coupling or channel gating, reducing the overall input/output gain. In any event, the above results lead to two important conclusions. First, $\rho 1$ and $\rho 2$ subunits form functional heteromeric receptors that mimic PTX resistance of native GABA_C responses in the rat retina. Second, PTX resistance appears to be based on the intrinsic structure of the $\rho 2$ subunit.

Site-Directed Mutagenesis Elucidates the Basis for PTX Resistance. To investigate the molecular basis for PTX resistance, we analyzed the amino acid sequence predicted by $\rho 1$

and $\rho 2$. We looked at the M2 region because of reports that PTX acted at least in part by blocking ligand-gated Cl^- channels (refs. 23 and 24, but see refs. 18, 25, and 26). Strikingly, in this region the $\rho 2$ clone differed from $\rho 1$ by only 2 amino acids (Fig. 5). At the first of these sites, however, both $\rho 1$ and $\text{h}\rho 1$ have a proline residue, while $\rho 2$ and $\text{h}\rho 2$ have a serine. This difference cannot account for PTX resistance conferred by $\rho 2$; data from Cutting and co-workers (27) suggest that, if anything, receptors composed of $\text{h}\rho 2$ subunits are more sensitive to PTX than $\text{h}\rho 1$ subunits, just the opposite of our findings with rat subunits. Moreover, this site is not conserved among GABA and glycine subunits (Fig. 5). In contrast, the amino acid residue at the second site of interest is conserved in all known GABA subunits as a threonine, except in $\rho 2$ where a methionine resides. This residue was therefore likely to be critical for PTX resistance.

To determine whether this amino acid residue contributes to PTX resistance, we performed site-directed mutagenesis to substitute a threonine for the methionine, yielding $\rho 2(\text{M}299\text{T})$. Similar to wild-type $\rho 2$, this mutant did not form functional homomeric GABA receptors. However, coexpression of $\rho 2(\text{M}299\text{T})$ with $\rho 1$ formed functional GABA receptors that were sensitive to PTX. These presumptive heteromeric receptors displayed virtually the same GABA dose-response and PTX-inhibition curves as homomeric $\rho 1$ receptors (data not shown). This raises the possibility, however, that $\rho 2(\text{M}299\text{T})$ cRNA was not functionally expressed and that only homomeric $\rho 1$ subunits contributed to these responses. This possibility is highly unlikely because of evidence for the formation of heteromeric $\rho 1/\rho 2(\text{M}299\text{T})$ receptors; GABA-evoked currents after coinjection of $\rho 1/\rho 2(\text{M}299\text{T})$ cRNAs were substantially smaller than those recorded after injection of $\rho 1$ cRNA alone but were very similar to their $\rho 1/\rho 2$ counterparts. Since $\rho 1/\rho 2$ receptors have a different pharmacology (PTX resistance) from homomeric $\rho 1$ receptors, we infer that heteromeric receptors were indeed formed. Taken together, these results suggest that substitution of threonine for methionine at residue 299 of $\rho 2$ eliminates PTX resistance of $\rho 1/\rho 2$ receptors. Since a methionine is normally present in this position, this site can account for the PTX resistance of native rat GABA_C receptors.

A remaining question is whether PTX resistance can also be influenced by residue 295 of $\rho 2$ (homologous to residue 310 in $\rho 1$). To investigate this, we used the ability of $\rho 1$ subunits to form homomeric receptors and made an additional mutant, $\rho 1(\text{P}310\text{S})$. Compared to wild type, homomeric $\rho 1(\text{P}310\text{S})$

receptors exhibited substantially smaller GABA-evoked currents. Consistent with the report of Cutting and co-workers (27), homomeric $\rho 1(\text{P}310\text{S})$ receptors displayed a higher EC_{50} ($9.1 \pm 1.4 \mu\text{M}$, mean \pm SEM; $n = 5$) and a substantial reduction in the effect of GABA concentration on PTX inhibition. The IC_{50} value of PTX for $2 \mu\text{M}$ GABA ($1.1 \pm 0.1 \mu\text{M}$; $n = 10$) was virtually the same as for $20 \mu\text{M}$ GABA ($1.2 \pm 0.1 \mu\text{M}$; $n = 7$). With the alteration in PTX antagonism in this mutant, we could not quantitatively compare PTX sensitivity to wild-type $\rho 1$ homomeric receptors. However, homomeric $\rho 1(\text{P}310\text{S})$ receptors, like $\text{h}\rho 2$, appear to be more sensitive to PTX than their wild-type $\rho 1$ counterparts. Thus, this residue cannot account for the PTX resistance conferred by the $\rho 2$ subunit.

If the native "substitution" of a methionine for a threonine at residue 299 of $\rho 2$ produced PTX resistance in heteromeric rat ρ receptors, then one might expect that site-directed mutagenesis of the homologous $\rho 1$ residue 314 would produce PTX-resistant $\rho 1$ mutant receptors. We therefore constructed the subunit $\rho 1(\text{T}314\text{M})$. Unfortunately, homomeric channels formed from this subunit displayed only very tiny GABA-evoked currents. Instead, we studied PTX sensitivity of receptors formed by coexpressing $\rho 1/\rho 1(\text{T}314\text{M})$. GABA-evoked currents decreased in magnitude as the percentage of $\rho 1(\text{T}314\text{M})$ cRNA increased (Fig. 3 D-F). The decrease in GABA-induced current was not due to a shift in the agonist dose-response curve since the EC_{50} was not significantly different for homomeric ($\rho 1/\rho 1$) vs. heteromeric $\rho 1/\rho 1(\text{T}314\text{M})$ receptors (data not shown). Qualitatively similar to the effect of $\rho 2$ on wild-type heteromeric receptors, PTX resistance increased with the proportion of injected $\rho 1(\text{T}314\text{M})$ cRNA (Figs. 3 D-F and 4A). However, the PTX dose-inhibition curve for $\rho 1(25\%)/\rho 1(\text{T}314\text{M})(75\%)$ was shifted to the right compared to $\rho 1(25\%)/\rho 2(75\%)$ (Fig. 4B).

DISCUSSION

Our results suggest that the PTX resistance of GABA_C responses in rat retina is due to $\rho 2$ subunits in heteromeric $\rho 1/\rho 2$ receptors. Moreover, a single amino acid in the M2 region of $\rho 2$ (methionine instead of threonine at residue 314 in $\rho 1$) is responsible for PTX resistance in the native receptor. The $\rho 1$ subunit differs from $\rho 2$ by an additional amino acid in the M2 region, corresponding to proline residue 310 in $\rho 1$ and serine residue 295 in $\rho 2$. However, substitution of serine for proline at this site in $\rho 1$ did not decrease PTX sensitivity. We therefore conclude that the proline/serine variation at this site is not the predominant factor conferring PTX resistance by the $\rho 2$ subunit, although this site might affect PTX sensitivity under other conditions. In fact, in an invertebrate GABA receptor subunit the mutation of alanine to serine at a homologous site abolished PTX sensitivity (28). In an α -helical structure, the two amino acids corresponding to residues 310 and 314 of $\rho 1$ could represent adjacent residues facing the pore (29), and thus each could affect PTX sensitivity. In any event, we find that a single amino acid residue located inside the predicted ion channel is critical for PTX action, lending further support to the notion that the channel itself is the major site of PTX blockade.

We also found that the amplitude of GABA-evoked currents of homomeric $\rho 1(\text{T}314\text{M})$ or $\rho 1(\text{P}310\text{S})$ receptors was significantly reduced compared to wild type. In addition, the GABA-induced currents of heteromeric $\rho 1/\rho 1(\text{T}314\text{M})$ receptors decreased in magnitude as we increased the amount of injected $\rho 1(\text{T}314\text{M})$ cRNA (Fig. 3 B and C). These results suggest that substitution of amino acid residues at these two sites, presumably facing the channel pore (29), may also affect channel gating, as previously demonstrated for acetylcholine receptors (30). This may at least partially account for the fact that receptors formed from homomeric $\rho 2$ subunits, containing serine and methionine residues at these two positions, displayed no detectable currents. Nonetheless, substitution of

M2 region of ligand-gated chloride channels

Gly $\alpha 1$	A R V	G L G I T	T V L T M T T Q S S G S R E
GABA $\text{dRd}1$	A R V	A L G V T	T V L T M T T L M S S T N A
GABA $\text{r}\alpha 1$	A R T	V F G V T	T V L T M T T L S I S A R N
GABA $\text{r}\beta 1$	A R V	A L G I T	T V L T M T T I S T H L R E
GABA $\text{r}\delta$	A R V	S L G I T	T V L T M T T L M V S A R S
GABA $\text{r}\gamma 1$	A R T	S L G I T	T V L T M T T L S T I A R K
GABA $\text{h}\rho 1$	A R V	P L G I T	T V L T M S T I I T G V N A
GABA $\text{h}\rho 2$	A R V	S L G I T	T V L T M T T I I T G V N A
GABA $\rho 1$	A R V	P L G I T	T V L T M S T I I T G V N A
GABA $\rho 2$	A R V	S L G I M	T V L T M S T I I T G V N A
	295	299	

FIG. 5. Comparison of M2 regions of ligand-gated Cl^- channels, including the rat glycine α subunit; the *Drosophila* GABA *Rdl* subunit; the rat GABA $\alpha 1$, $\beta 1$, $\gamma 1$, δ , $\rho 1$, and $\rho 2$ subunits; and the human $\rho 1$ and $\rho 2$ subunits. The 2 amino acid residues different in $\rho 1$ (residues 310 and 314) and $\rho 2$ (residues 295 and 299) are indicated by shaded areas. Note that in the $\rho 2$ subunit a methionine has replaced the threonine of the $\rho 1$ subunit at a site that is highly conserved among ligand-gated Cl^- channels.

the methionine with a threonine in $\rho 2$ did not restore detectable GABA-evoked currents. In contrast to $\rho 2$, $\rho 1$ subunits can form functional homomeric receptors, but the currents are substantially smaller than their $\rho 1$ counterparts (17). The N-terminal region is known to be critical for the assembly of functional ligand-gated receptors, including homomeric $\rho 2$ receptors (22, 31, 32). It is therefore possible that defects in both assembly and channel gating in the $\rho 2$ subunit prevent it from forming functional homomeric receptors.

It has been proposed that the two cloned human ρ subunits underlie the GABA_C responses of native receptors (16). However, prior to the present study, the subunit composition of this type of GABA receptor had not been elucidated. We took advantage of the PTX-resistant property of the rat retinal GABA_C receptor to discern the subunit composition of recombinant receptors. Since homomeric $\rho 1$ receptors are sensitive to PTX, we are able to show that $\rho 1$ and $\rho 2$ subunits form functional heteromeric GABA receptors because of their PTX resistance. It is therefore very likely that the native PTX-resistant GABA_C receptor in the rat retina is composed of both $\rho 1$ and $\rho 2$ subunits. However, the existence of additional ρ subunits cannot be excluded.

Our findings may provide an explanation not only for PTX resistance/sensitivity of GABA_C receptors but also for other vertebrate GABA receptors that are coupled to Cl⁻ channels, including the GABA_A subtype, which is inhibited by PTX (4, 33). PTX may therefore prove to be useful as a specific probe for examining motifs crucial to Cl⁻ permeability in a variety of receptor-channel complexes.

In summary, we demonstrate that a single amino acid residue in the $\rho 2$ subunit renders heteromeric $\rho 1/\rho 2$ receptors resistant to PTX. Our results lend further support to the proposal that GABA ρ subunits underlie the previously reported GABA_C responses in the retina of various species (6, 8). Recently, similar responses to GABA were reported in rat hippocampal neurons, suggesting that this form of ionotropic GABA receptor is more ubiquitous than previously thought (18). In a more general sense, the fact that a single amino acid residue can profoundly affect the PTX sensitivity of GABA receptors calls into question classification schemes based solely on pharmacological properties. Clearly, the ability to coassemble subunits to form functional heteromeric channels remains central to the definition of a receptor family. Our work, together with that of others (16), provides credence for the fulfillment of this concept by ρ subunits as the molecular basis for GABA_C responses.

We thank Dr. S. Nakanishi for the kind gift of a rat retinal cDNA library. This work was supported in part by the American Foundation for AIDS Research and National Institutes of Health Grant R01 EY05477.

- Roberts, E. (1986) in *Receptor Biochemistry and Methodology*, eds. Olsen, R. W. & Venter, J. C. (Liss, New York), Vol. 5, pp. 1–39.
- Johnston, G. R. A. (1986) in *Receptor Biochemistry and Methodology*, eds. Olsen, R. W. & Venter, J. C. (Liss, New York), Vol. 5, pp. 57–72.
- Hill, D. R. & Bowey, N. G. (1981) *Nature (London)* **290**, 149–152.
- Sivilotti, L. & Nistri, A. (1991) *Prog. Neurobiol.* **36**, 35–92.
- Qian, H. & Dowling, J. E. (1993) *Nature (London)* **361**, 162–164.
- Feigenspan, A., Wässle, H. & Bormann, J. (1993) *Nature (London)* **361**, 159–162.
- Polenzani, L., Woodward, R. M. & Milei, R. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 4318–4322.
- Pan, Z.-H. & Lipton, S. A. (1995) *J. Neurosci.* **15**, 2668–2679.
- Qian, H. & Dowling, J. E. (1994) *J. Neurosci.* **14**, 4299–4307.
- Dong, C.-J., Picaud, S. A. & Werblin, F. S. (1994) *J. Neurosci.* **14**, 2648–2658.
- Lukasiewicz, P. D., Maple, B. R. & Werblin, F. S. (1994) *J. Neurosci.* **14**, 1202–1212.
- Matthews, G., Ayoub, G. S. & Heidelberger, R. (1994) *J. Neurosci.* **14**, 1079–1090.
- Strata, F. & Cherubini, E. (1994) *J. Physiol. (London)* **480**, 493–503.
- Cutting, G. R., Lu, L., O'Hara, B. F., Kasch, L. M., Montrose-Rafizadeh, C., Donovan, D. M., Shimada, S., Antonarakis, S. E., Guggino, W. B., Uhl, G. R. & Kazazian H. H., Jr. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 2673–2677.
- Cutting, G. R., Currstin, S., Zoghbi, H., O'Hara, B., Seldin, M. F. & Uhl, G. R. (1992) *Genomics* **12**, 801–806.
- Shimada, S., Cutting, G. & Uhl, G. R. (1992) *Mol. Pharmacol.* **41**, 683–687.
- Wang, T.-L., Guggino, W. B. & Cutting, G. R. (1994) *J. Neurosci.* **14**, 6524–6531.
- Newland C. F. & Cull-Candy, S. G. (1992) *J. Physiol. (London)* **447**, 191–213.
- Zhang, D., Pan, Z.-H., Brideau, A. D. & Lipton, S. A. (1995) *Invest. Ophthalmol. Visual Sci. Suppl.* **36**, 285 (abstr.).
- Pan, Z.-H., Zhang, D., Brideau, A. D., Zhang, X. & Lipton, S. A. (1995) *Invest. Ophthalmol. Visual Sci. Suppl.* **36**, 285 (abstr.).
- Sullivan, J. M., Traynelis, S. F., Chen, H.-S. V., Escobar, W., Heinemann, S. F. & Lipton, S. A. (1994) *Neuron* **13**, 929–936.
- Hackam, A. S., Wang, T.-L., Guggino, W. B. & Cutting, G. R. (1995) *Invest. Ophthalmol. Visual Sci. Suppl.* **36**, 285 (abstr.).
- King, R. G., Nielsen, M., Stauber, G. B. & Olsen, R. W. (1987) *Eur. J. Biochem.* **169**, 555–562.
- Inoue, M. & Akaike, N. (1988) *Neurosci. Res.* **5**, 380–394.
- Smart, T. G. & Constanti, A. (1986) *Proc. R. Soc. London B* **227**, 191–216.
- Yoon, K.-W., Covey, D. F. & Rothman S. M. (1993) *J. Physiol. (London)* **464**, 423–439.
- Wang, T.-L., Hackam, A. S., Guggino, W. B. & Cutting, G. R. (1995) *Invest. Ophthalmol. Visual Sci. Suppl.* **36**, 285 (abstr.).
- Ffrench-Constant, R. H., Rocheleau, T. A., Steichen, J. C. & Chalmers, A. E. (1993) *Nature (London)* **363**, 449–451.
- Xu, M. & Akabas, M. H. (1993) *J. Biol. Chem.* **268**, 21505–21508.
- Villaroel, A. & Sakmann, B. (1992) *Biophys. J.* **62**, 196–208.
- Verrall, S. & Hall, Z. W. (1992) *Cell* **68**, 23–31.
- Kuhse, J., Laube, B., Magalei, D. & Betz, H. (1993) *Neuron* **11**, 1049–1056.
- Macdonald, R. L. & Olsen R. W. (1994) *Annu. Rev. Neurosci.* **17**, 569–602.